NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.

depicting IDO mechanism of action

NewLink Genetics Corp. CEO Chuck Link says he believes the company's IDO pathway inhibitor indoximod still has potential and is differentiated from direct inhibitors of the target, even after news of Genentech Inc.'s exit from an IDO/TDO development deal.

Indoleamine 2,3-dioxygenase (IDO) is an enzyme that plays an important part in immune response. NewLink has developed a direct inhibitor...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip